Home > Back to Publisher > Report Information

Pharmacy Liberalisation in Europe: Prospects and Implications

JustPharmaReports.com
September 1, 2008
76 Pages - SKU: JPM1906669

Abstract Table of Contents Related Reports

Countries covered: Europe

Very little in the pricing environment in Europe is predictable to pharmaceutical companies and only rarely is much notice given of change. But before the end of 2009, if the European Court of Justice accepts the arguments put to it forcefully by the European Commission and by DocMorris, revolutionary reform among industry’s main customer group, the community pharmacist, in several of the main countries, including 4 of the EU-5, will get the green light. The main issue to be resolved, whether national regulations on pharmacy ownership and establishment of new premises infringe EU law, is of wider importance than for the pharmacy profession alone. It amounts to a battle over control of healthcare provision between Brussels and the member states, with the outcome also of great significance to patients, wholesalers, manufacturers and payers.

‘Pharmacy Liberalisation in Europe: Prospects and Implications’ provides fully-researched, up-to-date information and interpretation on what deregulation could mean to all participants in the medicines’ market. Whether your interest is in marketing prescription brands, generics or OTCs, in their distribution, or in paying the bill for them, this report is for you. To be forewarned of what might happen will allow adequate preparation for it.

The report addresses:

Background and current status of infringement actions brought by the European Commission against seven EU member states, plus the key ECJ case involving the controversial DocMorris pharmacy in the German city of Saarbrücken.
The arguments for and against reform.
What might happen, who would be the winners and the losers.
Details of the current ownership structure, and ownership and establishment rules for pharmacies in countries all across Europe from Iceland to Cyprus.
Interdependency of pharmacy and wholesaling, and how this could evolve.
What lessons can be found from markets that have already deregulated.
How vertical integration impacts reimbursement of multisource products and the response by payers to this.
The latest on plans to break up Apoteket’s pharmacy monopoly in Sweden.

Executive Summary
1. Background: 1.1 Community Pharmacy; 1.2 Pharmacy Regulations; 1.3 Intervention by the European Commission; 1.4 Limitations on Commission Action
2. The Arguments: 2.1 National Developments; 2.2 Other Contributions to the Debate; 2.3 ECJ Oral Hearing in Italian and DocMorris Cases; 2.4 Other Commission Interventions Concerning Pharmacy
3. Deregulation to Date: 3.1 National Situation; 3.2 Liberalisation of OTC Sales Channels
4. What Could Happen: 4.1 More Pharmacies?; 4.2 Are More Pharmacies Needed?; 4.3 Greater Price Competition?; 4.4 Pharmacy Acquisition by Wholesalers?; 4.5 Pharmacy Acquisition by Other Types of Companies?; 4.6 Distribution Changes in Sweden?
5. Implications: 5.1 For Patients; 5.2 For Pharmacy; 5.3 For Other Professions; 5.4 For Wholesalers; 5.5 For Manufacturers; 5.6 For Governments/Third Party Payers
List of tables: 1.1 Pharmacy and pharmacist demography in Europe; 1.2 Share of medicine sales from wholesalers by customer group; 1.3 Is it possible for a non-pharmacist to own a pharmacy?; 1.4 Pharmacy regulation indices; 1.5 Timetable of EU proceedings against pharmacy regulations; 3.1 Pharmacies in Iceland; 3.2 Leading pharmacy chains in Ireland; 3.3 Leading pharmacy chains in Lithuania; 3.4 Leading pharmacy chains in the Netherlands; 3.5 Ownership structure of community pharmacies in Norway; 3.6 Evolution of pharmacy numbers and share of chains in England; 3.7 Evolution of supermarket pharmacies in UK; 3.8 Evolution of large pharmacy chains in UK; 4.1 Evolution of pharmacy numbers across Europe, 1995-2006; 4.2 Other access points for medicines in Europe; 4.3 Ranking of Europe’s ‘big 3’ wholesalers by country; 4.4 Pharmacy ownership by leading wholesalers; 4.5 Other wholesaler-owned pharmacy chains; 4.6 Share of community pharmacies in virtual chains
Appendices: 1. Pharmacy Ownership and Establishment Criteria, 2008; 2. European and National Pharmacy Associations

More Europe Regulation & Policy Reports

Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure by GBI Research
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure Summary GBI Research, the leading business intelligence provider, ...

Denmark Drug Patent Inventor Report - 2011 by DrugPatentWatch
TheDenmark Drug Patent Inventor Reportprofiles Denmark-based inventors leading pharmaceutical innovation. Using data on drugs approved from 2000 to 2010, this report provides complete lists of: Top ...

Belgium Drug Patent Inventor Report - 2011 by DrugPatentWatch
TheBelgium Drug Patent Inventor Reportprofiles Belgium-based inventors leading pharmaceutical innovation. Using data on drugs approved from 2000 to 2010, this report provides complete lists of: Top ...

Spain Drug Patent Inventor Report - 2011 by DrugPatentWatch
TheSpain Drug Patent Inventor Reportprofiles Spain-based inventors leading pharmaceutical innovation. Using data on drugs approved from 2000 to 2010, this report provides complete lists of: Top ...

Norway Drug Patent Inventor Report - 2011 by DrugPatentWatch
TheNorway Drug Patent Inventor Reportprofiles Norway-based inventors leading pharmaceutical innovation. Using data on drugs approved from 2000 to 2010, this report provides complete lists of: Top ...

See all reports like this >>

More Europe Reports

A Comprehensive Study Of The UK Video Conferencing Equipment Market In 2010, Rating & Valuing Each Of The 30 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Tableware Market In 2010, Rating & Valuing Each Of The 166 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Surveyors & Valuers Market In 2010, Rating & Valuing Each Of The 943 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Subsea Engineering Market In 2010, Rating & Valuing Each Of The 142 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Structural Engineering Consultancy Market In 2010, Rating & Valuing Each Of The 300 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

See all reports like this >>

Pharmacy Liberalisation in Europe: Prospects and Implications

Share this report

Other tasks

Research Assistance

Related Markets

Regulation & Policy Reports

Free Alert Me service